Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2016

Supporting Information for

Amino Acid-Promoted C-H Alkylation with Alkylboronic Acids Using a Removable

Directing Group

Yu Zhang, Hang Jiang, Dushen Chen, Yanghui Zhang*

Department of Chemistry, and Shanghai Key Lab of Chemical Assessment and Sustainability, Tongji

University, 1239 Siping Road, Shanghai, 200092, P. R. China.

*To whom correspondence should be addressed. Email: zhangyanghui@tongji.edu.cn

Table of Contents

I. General information	S2
II. Synthesis of pyridyl silanes and alkylboronic acids	S2
III. General procedure for the optimization of reaction conditions	S15
IV. General procedure for the C-H alkylation with alkylboronic acids	S16
V. Characterization of synthesized compounds	S17
VI. Removal of directing group	S27
VII. NMR spectra	S28

I. General information

All the solvents were purified by distillation prior to use. Unless otherwise noted, the other commercial chemicals were used without further purification. ¹H NMR and ¹³C NMR spectra were recorded on Bruker ARX400. High resolution mass spectra were measured on Bruker MicroTOFII ESI-TOF or EI-TOF (Agilent 6538 UHD) mass spectrometer. ¹H NMR spectra were recorded in CDCl₃, CD₃OD, or (CD₃)₂SO and referenced to residual CHCl₃ at 7.26 ppm, CH₃OH at 3.31 ppm, or (CH₃)₂SO at 2.50 ppm, respectively. ¹³C NMR spectra are referenced to the central peak of CDCl₃ at 77.0 ppm, CD₃OD at 49.00 ppm, and (CD₃)₂SO at 39.52 ppm, respectively. Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad resonance.

II. Synthesis of pyridyl silanes and alkylboronic acids





To a solution of aryl bromide or -iodide (10 mmol) in Et_2O (10 mL) was added dropwise a solution of *n*-butyllithium (4.0 mL, 2.5 M in hexane, 10 mmol) at 0 °C under argon atmosphere. The reaction mixture was stirred at 0 °C for 1 h.

The prepared phenylithium was added slowly via syringe to a solution of dichlorosilane (10 mmol) in solution of Et_2O (20 mL) at -73 °C under argon atmosphere. After 30 min, precipitation of salts was observed. After the addition was complete, the mixture was allowed to warm to room temperature over 2 h and was stirred for an additional 6 h. Hexane was added, and the slurry was Schlenk-filtered. The filtrate was concentrated *in vacuo* to afford chlorophenylsilane without further purification.

To a solution of 2-bromopyridine (0.98 mL, 10 mmol) in dry THF (20 mL) was added dropwise a solution of *n*-butyllithium (4.0 mL, 2.5 M in hexane, 10 mmol) at -78 $^{\circ}$ under argon atmosphere. The reaction mixture was stirred at -78 $^{\circ}$ for 2 h and then prepared chlorophenylsilane (10 mmol) was added dropwise. The resulting solution was allowed to warm to room temperature and was stirred overnight. The mixture was quenched with 10 mL of saturated NH₄Cl solution and extracted with ethyl acetate three times. The combined organic extracts were washed with brine, dried over the

anhydrous sodium sulfate, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to afford corresponding pyridyl silanes.

2-(diisopropyl(phenyl)silyl)pyridine (1a)



The product was prepared using the general procedure above and was isolated as a colorless liquid (2.31 g, 86% yield from iodobenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.85 (ddd, *J* = 4.9, 1.7, 1.1 Hz, 1H), 7.53 -7.58 (m, 3H), 7.50 (dt, *J* = 7.5, 1.3 Hz, 1H), 7.34 - 7.41 (m, 3H), 7.23 (ddd, *J* = 7.5, 4.9, 1.4 Hz, 1H), 1.68 (sept, *J* = 7.4 Hz, 2H), 1.01 (dd, J = 7.4, 5.0 Hz, 12H); ¹³C NMR (100 MHz, CDCl₃) δ 163.3, 149.9, 135.7, 133.2, 132.8, 131.7, 128.9, 127.4, 122.5, 17.4, 17.4, 9.9. HRMS (ESI-TOF) m/z: calcd for C₁₇H₂₃NNaSi⁺: 292.1492 (M + Na)⁺, found: 292.1492.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

2-(diisopropyl(p-tolyl)silyl)pyridine (1b)



The product was prepared using the general procedure above and was isolated as a colorless liquid (2.32 g, 82% yield from 1-iodo-4-methylbenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.93 – 8.88 (m, 1H), 7.61 (td, *J* = 7.5, 1.7 Hz, 1H), 7.57 – 7.54 (m, 1H), 7.52 (d, *J* = 7.9 Hz, 2H), 7.29 – 7.24 (m, 3H), 2.43 (s, 3H), 1.73 (sept, *J* = 7.38 Hz, 2H), 1.07 (t, *J* = 7.5 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 163.6, 150.0, 138.8, 135.9, 133.2, 131.9, 129.1, 128.4, 122.5, 21.4, 17.6, 17.5, 10.0. HRMS (ESI-TOF) m/z: calcd for C₁₈H₂₅NNaSi⁺: 306.1648 (M + Na)⁺, found: 306.1648. The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. *Angew*.

Chem., Int. Ed. 2010, 49, 8729.

2-(diisopropyl(4-methoxyphenyl)silyl)pyridine (1c)



The product was prepared using the general procedure above and was isolated as a white solid (2.45 g, 82% yield from 1-iodo-4-methoxybenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.86 – 8.83 (m, 1H), 7.56 (td, *J* = 7.6, 1.6 Hz, 1H), 7.49 (d, *J* = 8.6 Hz, 3H), 7.23 – 7.18 (m, 1H), 6.94 (d, *J* = 8.6 Hz, 2H), 3.82 (s, 3H), 1.65 (sept, *J* = 7.4 Hz, 2H), 1.00 (t, *J* = 6.9 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 163.8, 160.5, 150.0, 137.3, 133.2, 131.8, 123.5, 122.5, 113.4, 54.9, 17.6, 17.5, 10.2. HRMS (ESI-TOF) m/z: calcd for C₁₈H₂₅NNaOSi⁺: 322.1598 (M + Na)⁺, found: 322.1615.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

2-(diisopropyl(3-methoxyphenyl)silyl)pyridine (1d)



The product was prepared using the general procedure above and was isolated as a colorless liquid (2.45 g, 82% yield from 1-iodo-3-methoxybenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.84 (d, *J* = 4.7 Hz, 1H), 7.56 (t, *J* = 7.5 Hz, 1H), 7.51 (d, *J* = 7.4 Hz, 1H), 7.32 (t, *J* = 7.7 Hz, 1H), 7.24 – 7.19 (m, 1H), 7.12 (dd, *J* = 13.0, 4.8 Hz, 2H), 6.94 (dd, *J* = 8.1, 2.3 Hz, 1H), 3.79 (s, 3H), 1.67 (sept, *J* = 7.34 Hz, 2H), 1.01 (dd, *J* = 7.4, 3.7 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 163.2, 158.7, 150.0, 134.5, 133.3, 131.9, 128.7, 128.2, 122.6, 121.6, 114.1, 54.9, 17.6, 17.5, 10.0. HRMS (ESI-TOF) m/z: calcd for C₁₈H₂₅NNaOSi⁺: 322.1598 (M + Na)⁺, found: 322.1583.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

2-(diisopropyl(4-(trifluoromethyl)phenyl)silyl)pyridine (1e)



The product was prepared using the general procedure above and was isolated as a colorless liquid (2.43 g, 85% yield from1-iodo-4-(trifluoromethyl)benzene). ¹H NMR (400 MHz, CDCl₃) δ 8.90 (ddd, *J* = 4.8, 1.5, 1.0 Hz, 1H), 7.73 (d, *J* = 7.8 Hz, 2H), 7.69 – 7.61 (m, 3H), 7.54 (dd, *J* = 6.5, 1.1 Hz, 1H), 7.33 – 7.27 (m, 1H), 1.74 (sept, *J* = 7.34 Hz, 2H), 1.05 (dd, *J* = 7.4, 3.6 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 162.3, 150.3, 138.3, 136.1, 132.7 (q, *J*_{CF} = 15.6 Hz), 131.0 (q, *J*_{CF} = 32.2 Hz), 125.6, 124.2 (q, *J*_{CF} = 270.6 Hz), 124.0 (q, *J*_{CF} = 3.7 Hz), 122.9, 17.5, 17.4, 10.05. HRMS (ESI-TOF) m/z: calcd for C₁₈H₂₂F₃NNaSi⁺: 360.1366 (M + Na)⁺, found: 360.1366.

2-(diisopropyl(3-(trifluoromethyl)phenyl)silyl)pyridine (1f)



The product was prepared using the general procedure above and was isolated as a colorless liquid (2.70 g, 80% yield from 1-iodo-3-(trifluoromethyl)benzene). ¹H NMR (400 MHz, CDCl₃) δ 8.91 (d, J = 4.6 Hz, 1H), 7.85 (d, J = 6.5 Hz, 1H), 7.78 (t, J = 7.2 Hz, 1H), 7.74 – 7.62 (m, 2H), 7.54 (d, J = 5.3 Hz, 2H), 7.36 – 7.25 (m, 1H), 1.75 (sept, J = 7.5 Hz, 2H), 1.06 (dt, J = 8.0, 4.3 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 162.3, 150.3, 139.2, 134.6, 133.6, 132.1 (q, $J_{CF} = 15.2$ Hz), 131.8, 130.3, 129.8 (q, $J_{CF} = 31.5$ Hz), 127.8 (q, $J_{CF} = 212.4$ Hz), 125.8 (d, $J_{CF} = 13.2$ Hz), 123.0, 17.5, 17.4, 10.0. HRMS (ESI-TOF) m/z: calcd for C₁₈H₂₂F₃NNaSi⁺: 360.1366 (M + Na)⁺, found: 360.1360.

2-((4-fluorophenyl)diisopropylsilyl)pyridine (1g)



The product was prepared using the general procedure above and was isolated as a colorless liquid (1.88 g, 85% yield from 1-fluoro-4-iodobenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.84 (dd, J = 3.4, 1.1 Hz, 1H), 7.58 (td, J = 7.6, 1.7 Hz, 1H), 7.53 (ddd, J = 6.2, 5.2, 2.0 Hz, 2H), 7.50 – 7.46 (m, 1H), 7.23 (ddd, J = 7.6, 4.9, 1.3 Hz, 1H), 7.08 (t, J = 9.0 Hz, 2H), 1.70 – 1.61 (sept, J = 7.36 Hz, 2H), 0.99 (dd, J = 7.4, 4.0 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 165.0, 162.8 (d, $J_{CF} = 247.7$ Hz), 150.1, 137.7 (d, $J_{CF} = 7.3$ Hz), 133.4, 131.8, 128.3 (d, $J_{CF} = 3.9$ Hz), 122.7, 114.8 (d, $J_{CF} = 19.5$ Hz), 17.5, 17.4, 10.0. HRMS (ESI-TOF) m/z: calcd for C₁₇H₂₂FNNaSi⁺: 310.1398 (M + Na)⁺, found: 310.1398.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

2-((4-chlorophenyl)diisopropylsilyl)pyridine (1h)



The product was prepared using the general procedure above and was isolated as a colorless liquid (2.36 g, 78% yield from 1-chloro-4-iodobenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.86 – 8.82 (m, 1H), 7.57 (td, *J* = 7.6, 1.4 Hz, 1H), 7.48 (dd, *J* = 7.3, 5.8 Hz, 3H), 7.36 (d, *J* = 8.3 Hz, 2H), 7.25 –

7.19 (m, 1H), 1.65 (sept, J = 7.4 Hz, 2H), 0.99 (dd, J = 7.4, 4.5 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 162.7, 150.1, 137.1, 135.5, 133.4, 131.7, 131.3, 127.8, 122.8, 17.5, 17.4, 10.0. HRMS (ESI-TOF) m/z: calcd for C₁₇H₂₂ClNNaSi⁺: 326.1102 (M + Na)⁺, found: 326.1094.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

2-((3-chlorophenyl)diisopropylsilyl)pyridine (1i)



The product was prepared using the general procedure above and was isolated as a white solid (2.30 g, 76% yield from 1-chloro-3-iodobenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.84 (d, *J* = 4.8 Hz, 1H), 7.59 (td, *J* = 7.6, 1.1 Hz, 1H), 7.50 (dd, *J* = 8.8, 4.5 Hz, 2H), 7.42 (d, *J* = 7.2 Hz, 1H), 7.39 – 7.35 (m, 1H), 7.33 – 7.27 (m, 1H), 7.23 (dd, *J* = 4.5, 3.1 Hz, 1H), 1.72 – 1.60 (sept, *J* = 7.34 Hz, 2H), 1.00 (dd, *J* = 7.4, 2.1 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 162.4, 150.2, 135.9, 135.3, 134.0, 133.8, 133.5, 131.8, 129.2, 129.0, 122.8, 17.5, 17.4, 10.0. HRMS (ESI-TOF) m/z: calcd for C₁₇H₂₂ClNNaSi⁺: 326.1102 (M + Na)⁺, found: 326.1100.

2-((4-bromophenyl)diisopropylsilyl)pyridine (1j)



The product was prepared using the general procedure above and was isolated as a white solid (2.81 g, 81% yield from 1-bromo-4-iodobenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.84 (d, *J* = 4.7 Hz, 1H), 7.56 (dd, *J* = 7.6, 1.3 Hz, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 7.47 (d, *J* = 7.5 Hz, 1H), 7.42 (d, *J* = 8.2 Hz, 2H), 7.25 – 7.18 (m, 1H), 1.72 – 1.58 (sept, *J* = 7.36 Hz, 2H), 0.99 (dd, *J* = 7.4, 4.6 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 162.6, 150.1, 137.4, 133.5, 131.8, 131.8, 130.7, 124.1, 122.8, 17.5, 17.4, 9.9. HRMS (ESI-TOF) m/z: calcd for C₁₇H₂₃BrNSi⁺: 348.0778 (M + H)⁺, found: 348.0758. The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. *Angew. Chem., Int. Ed.* **2010**, *49*, 8729.

2-([1,1'-biphenyl]-4-yldiisopropylsilyl)pyridine (1k)



The product was prepared using the general procedure above and was isolated as a white solid (2.93 g, 85% yield from 4-bromo-1,1'-biphenyl). ¹H NMR (400 MHz, CDCl₃) δ 8.95 (d, J = 4.8 Hz, 1H), 7.75 – 7.68 (m, 7H), 7.64 (qd, J = 7.2, 1.3 Hz, 2H), 7.52 (t, J = 7.6 Hz, 2H), 7.45 – 7.40 (m, 1H), 7.30 (ddd, J = 6.9, 4.9, 2.2 Hz, 1H), 1.88 – 1.73 (sept, J = 7.36 Hz, 2H), 1.13 (dd, J = 7.3, 3.8 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 163.3, 150.1, 141.7, 141.0, 136.3, 133.3, 131.9, 131.6, 128.6, 127.2, 127.0, 126.2, 122.6, 17.6, 17.5, 10.1. HRMS (ESI-TOF) m/z: calcd for C₂₃H₂₇NNaSi⁺: 368.1805 (M + Na)⁺, found: 368.1805.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

2-((3,4-dimethylphenyl)diisopropylsilyl)pyridine (1n)



The product was prepared using the general procedure above and was isolated as a colorless liquid (2.43 g, 82% yield from 4-iodo-1,2-dimethylbenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.87 (d, *J* = 4.8 Hz, 1H), 7.57 (td, *J* = 7.5, 1.6 Hz, 1H), 7.53 (t, *J* = 6.9 Hz, 1H), 7.32 (d, *J* = 7.6 Hz, 2H), 7.25 – 7.20 (m, 1H), 7.18 (d, *J* = 7.3 Hz, 1H), 2.30 (s, 3H), 2.29 (s, 3H), 1.78 – 1.61 (sept, *J* = 7.35 Hz, 2H), 1.03 (t, *J* = 7.5 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 163.8, 150.0, 137.6, 137.1, 135.6, 133.6, 133.2, 131.9, 129.6, 128.9, 122.5, 19.8, 19.7, 17.6, 17.5, 10.0. HRMS (ESI-TOF) m/z: calcd for C₁₉H₂₇NNaSi⁺: 320.1805 (M + Na)⁺, found: 320.1805.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

2-((4-fluoro-3-methylphenyl)diisopropylsilyl)pyridine (10)



The product was prepared using the general procedure above and was isolated as a colorless liquid (2.23 g, 74% yield from 1-fluoro-4-iodo-2-methylbenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.87 – 8.82 (m, 1H), 7.58 (td, *J* = 7.6, 1.6 Hz, 1H), 7.49 (d, *J* = 7.5 Hz, 1H), 7.34 (t, *J* = 6.9 Hz, 2H), 7.25 – 7.18 (m, 1H), 7.02 (dd, *J* = 9.9, 8.3 Hz, 1H), 2.27 (d, *J* = 1.4 Hz, 3H), 1.65 (sept, *J* = 7.34 Hz, 2H), 0.99 (dd, *J* = 7.4, 3.7 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 163.6, 163.2, 161.2, 150.1, 139.1 (d, *J*_{CF} = 4.9 Hz), 135.1 (d, *J*_{CF} = 7.5 Hz), 132.6 (d, *J*_{CF} = 162.3 Hz), 128.0 (d, *J*_{CF} = 4.6 Hz), 124.0 (d, *J*_{CF} = 15.8 Hz), 122.7, 114.4 (d, *J*_{CF} = 20.7 Hz), 17.5, 17.4, 14.5 (d, *J*_{CF} = 3.8 Hz), 10.0. HRMS (ESI-TOF) m/z: calcd for C₁₈H₂₄FNNaSi⁺: 324.1554 (M + Na)⁺, found: 324.1550. The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. *Angew*.

Chem., Int. Ed. 2010, 49, 8729.

2-(diisopropyl(naphthalen-2-yl)silyl)pyridine (1p)



The product was prepared using the general procedure above and was isolated as a white solid(2.68 g, 84% yield from 2-bromonaphthalene). ¹H NMR (400 MHz, CDCl₃) δ 8.96 (dd, J = 3.4, 1.1 Hz, 1H), 8.17 (s, 1H), 7.94 – 7.87 (m, 3H), 7.72 – 7.67 (m, 1H), 7.67 – 7.62 (m, 1H), 7.63 – 7.60 (m, 1H), 7.58 – 7.54 (m, 2H), 7.31 (ddd, J = 6.9, 4.9, 1.9 Hz, 1H), 1.86 (sept, J = 7.34 Hz, 2H), 1.14 (t, J = 7.7 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 163.4, 150.1, 136.9, 133.7, 133.2, 132.8, 131.9, 130.6, 128.1, 127.6, 126.6, 126.3, 125.7, 122.7, 17.7, 17.6, 10.2. HRMS (ESI-TOF) m/z: calcd for C₂₁H₂₅NNaSi⁺: 342.1648 (M + Na)⁺, found: 342.1623.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

2-(diethyl(phenyl)silyl)pyridine (4a)



The product was prepared using the general procedure above and was isolated as a colorless liquid (1.93 g, 80% yield from iodobenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.85 – 8.81 (m, 1H), 7.61 – 7.57 (m, 2H), 7.55 (td, *J* = 7.6, 1.7 Hz, 1H), 7.46 (d, *J* = 7.5 Hz, 1H), 7.40 – 7.35 (m, 3H), 7.19 (ddd, *J* = 7.5, 4.9, 1.3 Hz, 1H), 1.20 (dt, *J* = 9.8, 6.8 Hz, 4H), 1.06 (t, *J* = 7.7 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 165.2, 150.1, 135.3, 134.7, 133.6, 130.4, 129.1, 127.7, 122.6, 7.3, 3.4. HRMS (ESI-TOF) m/z: calcd for C₁₅H₂₀NSi⁺: 242.1360 (M + H)⁺, found: 242.1353.

2-(isobutyl(methyl)(phenyl)silyl)pyridine (4b)



The product was prepared using the general procedure above and was isolated as a colorless liquid (2.01 g, 79% yield from iodobenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.8 Hz, 1H), 7.62 (dd, *J* = 6.4, 3.0 Hz, 2H), 7.53 (td, *J* = 7.6, 1.7 Hz, 1H), 7.44 (d, *J* = 7.5 Hz, 1H), 7.40 – 7.32 (m, 3H), 7.18 (ddd, *J* = 7.5, 4.9, 1.3 Hz, 1H), 1.90 (dt, *J* = 13.4, 6.7 Hz, 1H), 1.22 (qd, *J* = 14.9, 7.0 Hz, 2H), 0.92 (dd, *J* = 6.6, 2.9 Hz, 6H), 0.69 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 166.6, 150.1, 137.0, 134.4, 133.8, 129.8, 129.0, 127.7, 122.6, 26.2, 26.1, 24.7, 23.8, -4.4. HRMS (ESI-TOF) m/z: calcd for C₁₆H₂₁NNaSi⁺: 278.1335 (M + Na)⁺, found: 278.1351.

2. Procedure for the preparation of 11 and 1m^[4]



To a solution of aryl bromide (1.04 g, 3 mmol) in Et₂O (8 mL) was added dropwise a solution of *n*-butyllithium (1.2 mL, 2.5 M in hexane, 3 mmol) at 0 $^{\circ}$ C under argon atmosphere. The reaction mixture was stirred at 0 $^{\circ}$ C for 1 h and then was added via cannula a solution of an appropriate electrophile (9 mmol) in Et₂O (8 ml) at -78 $^{\circ}$ C. After being stirred for 2 h at -78 $^{\circ}$ C, the solution was allowed to warm to room temperature overnight. The reaction was quenched with 10 mL of saturated NH₄Cl solution and extracted with ethyl acetate three times. The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the corresponding *para*-substituted aryl pyridyl silane.

ethyl 4-(diisopropyl(pyridin-2-yl)silyl)benzoate (11)



The product was prepared using the procedure above and was isolated as a white solid (0.94 g, 92% yield from 2-((4-bromophenyl)diisopropylsilyl)pyridine). ¹H NMR (400 MHz, CDCl₃) δ 8.82 (d, *J* = 4.3 Hz, 1H), 8.02 (d, *J* = 8.1 Hz, 2H), 7.63 (d, *J* = 8.1 Hz, 2H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 6.1 Hz, 2H), 7.63 (d, *J* = 8.1 Hz, 2H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 6.1 Hz, 2H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 6.1 Hz, 2H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 6.1 Hz, 2H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.45 (t, J = 7

7.5 Hz, 1H), 7.22 (dd, J = 6.6, 5.7 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 1.67 (dt, J = 14.7, 7.3 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H), 0.98 (dd, J = 7.3, 4.5 Hz, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 166.6, 162.5, 150.1, 139.5, 135.7, 133.4, 131.8, 130.9, 128.1, 122.8, 60.8, 17.4, 17.4, 14.2, 10.0. HRMS (ESI-TOF) m/z: calcd for C₂₀H₂₇NNaO₂Si⁺: 364.1703 (M + Na)⁺, found: 364.1703.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

4-(diisopropyl(pyridin-2-yl)silyl)-N,N-diisopropylbenzamide (1m)



The product was prepared using the procedure above and was isolated as a white solid (1.07 g, 90% yield from 2-((4-bromophenyl)diisopropylsilyl)pyridine). ¹H NMR (400 MHz, CDCl₃) δ 8.87 – 8.81 (m, 1H), 7.60 (td, *J* = 7.6, 1.7 Hz, 1H), 7.54 (d, *J* = 8.1 Hz, 2H), 7.51 (d, *J* = 7.5 Hz, 1H), 7.30 (d, *J* = 8.0 Hz, 2H), 7.25 – 7.21 (m, 1H), 3.97 (s, 1H), 3.51 (s, 1H), 1.65 (dt, *J* = 14.7, 7.4 Hz, 2H), 1.54 (s, 6H), 1.16 (s, 6H), 0.99 (m, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 171.0, 162.9, 150.1, 139.3, 136.0, 133.8, 133.5, 131.9, 124.8, 122.8, 20.7, 17.5, 17.4, 10.0. HRMS (ESI-TOF) m/z: calcd for C₂₄H₃₇N₂OSi⁺: 397.2670 (M + H)⁺, found: 397.2661.

The NMR data are identical to: Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

3. Procedure for the preparation of 2-(butyldimethylsilyl)pyridine 6a^[3]



To a solution of 2-bromopyridine (0.98 mL, 10 mmol) in dry THF (20 mL) was added dropwise a solution of *n*-butyllithium (4.0 mL, 2.5 M in hexane, 10 mmol) at -78 $^{\circ}$ C under argon atmosphere. The reaction mixture was stirred at -78 $^{\circ}$ C for 2 h and then neat butylchlorodimethylsilane (0.95 mL, 10 mmol) was added dropwise. The resulting solution was allowed to warm to room temperature and was stirred overnight. The mixture was quenched with 10 mL of saturated NH₄Cl solution and extracted with ethyl acetate three times. The combined organic organic extracts were washed with brine, dried over the anhydrous sodium sulfate, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to afford 2-(butyldimethylsilyl)pyridine.

2-(butyldimethylsilyl)pyridine (6a)



The product was prepared using the procedure above and was isolated as a colorless liquid (1.39 g, 72% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.75 (d, *J* = 4.8 Hz, 1H), 7.55 (t, *J* = 7.6 Hz, 1H), 7.46 (d, *J* = 7.5 Hz, 1H), 7.18 – 7.13 (m, 1H), 1.34 – 1.26 (m, 4H), 0.87 – 0.77 (m, 5H), 0.29 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 167.9, 150.0, 133.7, 128.9, 122.5, 26.4, 25.9, 14.5, 13.6, -3.6. HRMS (ESI-TOF) m/z: calcd for C₁₁H₂₀NSi⁺: 194.1360 (M + H)⁺, found: 194.1357.

4. Procedure for the preparation of 2-(dimethyl(phenyl)germyl)pyridine 8a^{[1][2][3]}



To a solution of aryl bromide or -iodide (6 mmol) in Et_2O (10 mL) was added dropwise a solution of *n*-butyllithium (2.4 mL, 2.5 M in hexane, 6 mmol) at 0 °C under argon atmosphere. The reaction mixture was stirred at 0 °C for 1 h.

The prepared phenylithium was added slowly via syringe to a solution of dichlorodimethylgermane (0.69 mL, 6 mmol) in solution of Et_2O (10 mL) at -73 °C under argon atmosphere. After 30 min, precipitation of salts was observed. After the addition was complete, the mixture was allowed to warm to room temperature over 2 h and was stirred for an additional 6 h. Hexane was added, and the slurry was Schlenk-filtered. The filtrate was concentrated to afford chlorodimethyl(phenyl)germane without further purification.

To a solution of 2-bromopyridine (0.58 mL, 6 mmol) in dry THF (10 mL) was added dropwise a solution of *n*-butyllithium (2.4 mL, 2.5 M in hexane, 6 mmol) at -78 $^{\circ}$ C under argon atmosphere. The reaction mixture was stirred at -78 $^{\circ}$ C for 2 h and then prepared chlorodimethyl(phenyl)germane (6 mmol) was added dropwise. The resulting solution was allowed to warm to room temperature and was stirred overnight. The mixture was quenched with 10 mL of saturated NH₄Cl solution and extracted with ethyl acetate three times. The combined organic extracts were washed with brine, dried over the anhydrous sodium sulfate, and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to afford 2-(dimethyl(phenyl)germyl)pyridine.

2-(dimethyl(phenyl)germyl)pyridine (8a)



The product was prepared using the procedure above and was isolated as a colorless liquid (1.43 g, 92% yield from iodobenzene). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, *J* = 4.6 Hz, 1H), 7.60 – 7.58 (m, 1H), 7.57 (d, *J* = 1.9 Hz, 1H), 7.54 (td, *J* = 7.6, 1.8 Hz, 1H), 7.45 – 7.41 (m, 1H), 7.41 – 7.35 (m, 3H), 0.75 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 168.6, 150.2, 139.3, 134.0, 133.5, 129.0, 128.5, 128.0, 122.5, -3.7. HRMS (ESI-TOF) m/z: calcd for C₁₃H₁₆GeN⁺: 260.0489 (M + H)⁺, found: 260.0488.

Cul (10 mol%) PPh3 (20 mol%) (i) RBr + Bpin-Bpin RBpin MeOLi (2.0 equiv) (1.5 equiv) DMF, N₂, 35 °C, 18 h KHF₂ (4.5M, 10 equiv) (ii) RBpin **RBF**₃K MeOH, rt, 12 h TMSCI (3.0 equiv) (iii) RB(OH)₂ RBF₃K CH₃CN/H₂O, rt, 12 h

5. General procedure for the preparation of alkylboronic acids^[5]

CuI (0.1905 g, 1.0 mmol), PPh₃ (0.5246 g, 2.0 mmol), LiOMe (0.7594 g, 20.0 mmol), and bis(pinacolato)diboron (3.80 g, 15.0 mmol) were added to a Schlenk tube equipped with a stir bar. The vessel was evacuated and filled with argon (three times). DMF (20 mL), the corresponding alkyl bromide (10.0 mmol) were added in turn by syringe under an argon atmosphere (if the alkyl bromide is a solid, it was added along with the CuI). The resulting reaction mixture was stirred vigorously at 35 °C for 18 h. The reaction mixture was then diluted with EtOAc, filtered through silica gel with copious washings (Et₂O or EtOAc), concentrated, and purified by column chromatography to afford corresponding alkylboronic esters.

To a solution of prepared pinacol ester in methanol (18 mL) was added 4.5 M KHF₂ (aq) (10 equiv.) {NOTE: KHF₂ is corrosive and discolours glassware after prolonged exposure.} The resulting mixture was stirred for 12 h, and then concentrated to dryness. The residue, a white solid, was extracted with hot acetone (20 ml) two times, and the combined filtered extracts were concentrated to a volume of ca. 4 mL. Ether (50 mL) was added and the resultant precipitate was collected and dried to afford corresponding potassium trifluoroborate as a white solid.

The prepared potassium trifluoroborate was dissolved in acetonitrile (20 mL) and water (9 mL) before addition of trimethylsilylchloride (3 equiv.). The resultant mixture was stirred for 12 h, before concentrating to a volume of ca. 4 mL. Saturated sodium bicarbonate solution (2 mL) and water (10 mL) were added to the residue, before extraction with ethyl acetate (10 mL) for two times. The

combined extracts were washed with near saturated brine, dried (Na₂SO₄), and the solvent was removed to provide corresponding alkylboronic acds as a white solid.

(4-phenylbutyl)boronic acid (2d)

The product was prepared using the general procedure above and was isolated as a white solid (1.48 g, 83% yield). ¹H NMR (400 MHz, d_6 -DMSO) δ 7.38 (s, 2H), 7.26 (t, J = 7.4 Hz, 2H), 7.20 – 7.12 (m, 3H), 2.57 – 2.51 (m, 2H), 1.51 (dt, J = 15.3, 7.5 Hz, 2H), 1.34 (dt, J = 15.2, 7.6 Hz, 2H), 0.66 – 0.55 (m, 2H). ¹³C NMR (100 MHz, d_6 -DMSO) δ 142.5, 128.2, 128.1, 125.4, 35.1, 34.1, 23.9. HRMS (ESI-TOF) m/z: calcd for C₁₀H₁₅BNaO₂⁺: 201.1057 (M + Na)⁺, found: 201.1100.

(4-methoxybutyl)boronic acid (2e)

The product was prepared using the general procedure above and was isolated as a white solid (0.95 g, 72% yield). ¹H NMR (400 MHz, d_6 -DMSO) δ 7.38 (s, 2H), 3.27 (t, J = 6.5 Hz, 2H), 3.19 (s, 3H), 1.48 – 1.39 (m, 2H), 1.32 (dt, J = 14.8, 7.4 Hz, 2H), 0.57 (t, J = 7.7 Hz, 2H). ¹³C NMR (100 MHz, d_6 -DMSO) δ 71.9, 57.7, 31.9, 20.8. HRMS (ESI-TOF) m/z: calcd for C₅H₁₃BNaO₃⁺: 155.0850 (M + Na)⁺, found: 155.0851.

(4-cyanobutyl)boronic acid (2f)

The product was prepared using the general procedure above and was isolated as a white solid (0.75 g, 77% yield). ¹H NMR (400 MHz, d_6 -DMSO) δ 7.47 (s, 2H), 2.44 (t, J = 6.9 Hz, 2H), 1.54 – 1.45 (m, 2H), 1.44 – 1.34 (m, 2H), 0.59 (t, J = 7.7 Hz, 2H). ¹³C NMR (100 MHz, d_6 -DMSO) δ 120.7, 27.4, 23.4, 16.0. HRMS (ESI-TOF) m/z: calcd for C₅H₁₀BNNaO₂⁺: 150.0697 (M + Na)⁺, found: 150.0718.

(4-(furan-2-yl)butyl)boronic acid (2g)

The product was prepared using the general procedure above and was isolated as a white solid (1.37 g, 82% yield). ¹H NMR (400 MHz, d_6 -DMSO) δ 7.47 (d, J = 1.0 Hz, 1H), 7.40 (s, 2H), 6.32 (dd, J = 2.9, 1.9 Hz, 1H), 6.05 (d, J = 2.5 Hz, 1H), 2.55 (t, J = 7.5 Hz, 2H), 1.52 (dt, J = 15.2, 7.5 Hz, 2H), 1.40 – 1.30 (m, 2H), 0.62 – 0.57 (m, 2H). ¹³C NMR (100 MHz, CD₃OD) δ 157.6, 141.7, 110.9, 105.5, 31.9, 28.7, 24.4.

4-(1,3-dioxoisoindolin-2-yl)butylboronic acid (2h)



The product was prepared using the general procedure above and was isolated as a white solid (1.83 g, 74% yield). ¹H NMR (400 MHz, d_6 -DMSO) δ 7.88 – 7.80 (m, 4H), 7.40 (s, 2H), 3.54 (t, J = 7.0 Hz, 2H), 1.53 – 1.47 (m, 2H), 1.31 – 1.27 (m, 2H), 0.59 (t, J = 7.8 Hz, 2H). ¹³C NMR (100 MHz, d_6 -DMSO) δ 167.9, 134.3, 131.6, 122.9, 37.4, 30.8, 21.5. HRMS (ESI-TOF) m/z: calcd for C₁₂H₁₄BNNaO₄⁺: 270.0908 (M + Na)⁺, found: 270.0908.

The data are identical to: Shao, X.; Liu, T.; Lu, L.; Shen, Q.-L. Org. Lett. 2014, 16, 4738.

(4-(4-acetylphenoxy)butyl)boronic acid (2i)



The product was prepared using the general procedure above and was isolated as a white solid (1.58 g, 67% yield). ¹H NMR (400 MHz, d_6 -DMSO) δ 7.90 (d, J = 8.9 Hz, 2H), 7.44 (s, 2H), 7.01 (d, J = 8.9 Hz, 2H), 4.02 (t, J = 6.5 Hz, 2H), 2.50 (s, 3H), 1.74 – 1.63 (m, 2H), 1.46 (dt, J = 15.3, 7.7 Hz, 2H), 0.63 (t, J = 7.9 Hz, 2H). ¹³C NMR (100 MHz, d_6 -DMSO) δ 196.2, 162.6, 130.4, 129.6, 114.1, 67.8, 31.2, 26.3, 20.6. HRMS (ESI-TOF) m/z: calcd for C₁₂H₁₇BNaO₄⁺: 259.1112 (M + Na)⁺, found: 259.1114.

(4-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)butyl)boronic acid (2j)



The product was prepared using the general procedure above and was isolated as a white solid (1.68 g, 61% yield). ¹H NMR (400 MHz, d_6 -DMSO) δ 7.67 (d, J = 9.5 Hz, 1H), 7.45 (s, 2H), 6.97 – 6.93 (m, 2H), 6.20 (d, J = 1.0 Hz, 1H), 4.05 (t, J = 6.5 Hz, 2H), 2.39 (s, 3H), 1.74 – 1.64 (m, 2H), 1.52 – 1.43 (m, 2H), 0.64 (t, J = 7.8 Hz, 2H). ¹³C NMR (100 MHz, d_6 -DMSO) δ 161.8, 160.1, 154.7, 153.4, 126.4, 112.9, 112.4, 110.9, 101.0, 68.2, 31.2, 20.6, 18.1. HRMS (ESI-TOF) m/z: calcd for C₁₄H₁₇BNaO₅⁺: 299.1061 (M + Na)⁺, found: 299.1053.

The data are identical to: Shao, X.; Liu, T.; Lu, L.; Shen, Q.-L. Org. Lett. 2014, 16, 4738.

(4-(((8S,9R,13R,14R)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a] phenanthren-3-yl)oxy)butyl)boronic acid (2k)



The product was prepared using the general procedure above and was isolated as a white solid (2.11 g, 57% yield). ¹H NMR (400 MHz, d_6 -DMSO) δ 7.42 (s, 2H), 7.15 (d, J = 8.6 Hz, 1H), 6.66 (dd, J = 8.5, 2.6 Hz, 1H), 6.60 (d, J = 2.3 Hz, 1H), 3.87 (t, J = 6.5 Hz, 2H), 2.84 – 2.76 (m, 2H), 2.43 (dd, J = 18.7, 8.2 Hz, 1H), 2.33 (s, 1H), 2.17 (s, 1H), 2.11 – 2.00 (m, 1H), 1.94 (m, 2H), 1.75 (d, J = 6.9 Hz, 1H), 1.68 – 1.57 (m, 2H), 1.57 – 1.40 (m, 5H), 1.41 – 1.29 (m, 3H), 0.82 (s, 3H), 0.62 (t, J = 7.8 Hz, 2H). ¹³C NMR (100 MHz, d_6 -DMSO) δ 219.7, 156.6, 137.3, 131.5, 126.2, 114.1, 112.0, 67.2, 60.5, 49.6, 47.3, 43.4, 37.9, 35.4, 31.6, 31.4, 29.2, 26.1, 25.5, 21.2, 20.8, 13.5. HRMS (ESI-TOF) m/z: calcd for C₂₂H₃₁BNaO₄⁺: 393.2208 (M + Na)⁺, found: 393.2213.

The data are identical to: Shao, X.; Liu, T.; Lu, L.; Shen, Q.-L. Org. Lett. 2014, 16, 4738.

Reference:

[1] Huang, W.-L.; Dulong, F.; Khan, S. I.; Cantat, T.; Diaconescu, P. L. J. Am. Chem. Soc. **2014**, *136*, 17410.

[2] Denmark, S. E.; Hurd, A. R.; Sacha, H. J. J. Org. Chem. 1997, 62, 1668.

[3] Itami, K.; Mitsudo, K.; Fujita, K.; Ohashi, Y.; Yoshida, J. J. Am. Chem. Soc. 2004, 126, 11058.

[4] Dudnik, A. S.; Chernyak, N.; Huang, C.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 8729.

[5] Xu, J.; Xiao, B.; Xie, C.-Q.; Luo, D.-F.; Liu, L.; Fu. Y. Angew. Chem., Int. Ed. 2012, 51, 12551.

III. General procedure for the optimization of the reaction conditions



A 35 mL tube, equipped with a magnetic stir bar, was charged with $Pd(OAc)_2$ (0.0045 g, 0.02 mmol, 10 mol%) followed by 2-(diisopropyl(phenyl)silyl)pyridine (54 µL, 0.2 mmol), butylboronic acid, ligand, oxidant, additives, and solvent. The tube was placed into an oil bath under desired temperature. After the reaction was completed, it was allowed to cool to room temperature. The reaction mixture was diluted with ethyl acetate and then filtered through a small pad of Celite. The filtrate was concentrated *in vacuo*. The yield was determined by ¹H NMR analysis of crude product using Cl₂CHCHCl₂ as the internal standard.

	,i-Pr Si−i-Pr + n-	Bu(OH) ₂ .	Pd(O, Liga BC Ag ₂ C	Ac) ₂ (10 mol%) nd (20 mol%) (1.2 equiv) O ₃ (2.0 equiv)	, <i>i</i> -Pr N Si- <i>i</i> -Pr <i>n</i> -Bu
			NaHC THF	CO ₃ (1.0 equiv)	
	1a	2a		,	3aa
entry	Ligand	yie l d (%)	^b entry	/ Ligand	yield (%) ^b
1	Ac-Gly-OH	89	11	L-Proline	0
2	Ac-Leu-OH	32	12	Boc-Ser-OH	32
3	Ac-IIe-OH	17	13	N-Cbz-O-tBu-Ser	-OH trace
4	Boc-Leu-OH	trace	14	Ac-Glu-OH	0
5	Boc-lle-OH	18	15	Boc-Glu-OH	55
6	Boc-Gly-OH	trace	16	Ac-Cys-OH	0
7	Cbz-Gly-OH	42	17	Ac-Tyr-OH	trace
8	Ac-Ala-OH	31	18	PivOH	22
9	Ac-Val-OH	47			
10	Boc-Abu-OH	32			

Table 1. Ligand Survey for PyrDipSi-Directed C-H alkylation with Alkylboronic Acid

^{*a*}Reaction conditions: **1a** (0.2 mmol), **2a** (0.6 mmol, 3.0 equiv), $Pd(OAc)_2$ (0.02 mmol, 10 mol%), ligand (0.04 mmol, 20 mol%), BQ (0.24 mmol, 1.2 equiv), Ag_2CO_3 (0.4 mmol, 2.0 equiv), NaHCO₃ (0.2 mmol, 1.0 equiv), THF (1.0 mL), air, 60 °C, 48 h. ^{*b*}Determined by ¹H NMR analysis of the crude reaction mixtures using CHCl₂CHCl₂ as an internal standard.

IV. General procedure for the C-H alkylation with alkylboronic acids

A 35 mL tube, equipped with a magnetic stir bar, was charged with $Pd(OAc)_2$ (0.0045 g, 0.02 mmol, 10 mol%) followed by pyridyl silanes (0.2 mmol), alkylboronic acid (0.0612 g, 0.6 mmol), Ac-Gly-OH (0.0046 g, 0.04 mmol), BQ (0.0218 g, 0.24 mmol), Ag₂CO₃ (0.1102 g, 0.4 mmol), NaHCO₃ (0.0168g, 0.2 mmol) and THF (1.0 mL). The tube was placed into an oil bath preheated to 60 °C. After the reaction mixture was stirred for 48 h, it was allowed to cool to room temperature. The reaction mixture was diluted with ethyl acetate and then filtered through a small pad of Celite. The filtrate was concentrated *in vacuo* and the residue was purified by silica gel column chromatography affording the corresponding products.

V. Characterization of synthesized compounds

2-((2-butylphenyl)diisopropylsilyl)pyridine (3aa)

Colorless liquid (58.5 mg, 90%). ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.6 Hz, 1H), 7.56 (td, *J* = 7.6, 1.7 Hz, 1H), 7.48 (dd, *J* = 7.4, 1.4 Hz, 2H), 7.36 – 7.31 (m, 1H), 7.26 – 7.14 (m, 3H), 2.42 – 2.34 (m, 2H), 1.73 – 1.70 (m, 2H), 1.45 – 1.36 (m, 2H), 1.06 (d, *J* = 7.4 Hz, 6H), 1.03 – 0.97 (m, 8H), 0.71 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 149.9, 149.8, 136.8, 133.3, 131.3, 131.1, 129.2, 128.6, 124.6, 122.4, 36.8, 33.6, 22.9, 18.2, 17.9, 13.8, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₁H₃₁NNaSi⁺: 348.2118 (M + Na)⁺, found: 348.2118.

2-((2-butyl-4-methylphenyl)diisopropylsilyl)pyridine (3ba)

Colorless liquid (56.3 mg, 83%). ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.7 Hz, 1H), 7.56 (td, *J* = 7.6, 1.6 Hz, 1H), 7.47 (d, *J* = 7.5 Hz, 1H), 7.38 (d, *J* = 7.6 Hz, 1H), 7.21 (ddd, *J* = 7.5, 4.9, 1.3 Hz, 1H), 7.08 (s, 1H), 7.01 (d, *J* = 7.6 Hz, 1H), 2.38 – 2.30 (m, 5H), 1.73 – 1.70 (m, 2H), 1.50 – 1.31 (m, 2H), 1.05 (d, *J* = 7.4 Hz, 6H), 1.03 – 0.97 (m, 8H), 0.72 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 149.8, 139.0, 136.9, 133.3, 132.0, 131.2, 129.5, 127.7, 125.6, 122.4, 36.7, 33.6, 22.9, 21.4, 18.2, 18.0, 13.7, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₂H₃₃NNaSi⁺: 362.2274 (M + Na)⁺, found: 362.2265.

2-((2-butyl-4-methoxyphenyl)diisopropylsilyl)pyridine (3ca)

Colorless liquid (29.8 mg, 42%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, J = 4.5 Hz, 1H), 7.55 (t, J = 7.0 Hz, 1H), 7.47 (d, J = 7.4 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.23 – 7.16 (m, 1H), 6.81 (d, J = 2.0

Hz, 1H), 6.78 - 6.71 (m, 1H), 3.81 (s, 3H), 2.41 - 2.32 (m, 2H), 1.71 - 1.67 (m, 4H), 1.47 - 1.36 (m, 2H), 1.05 (d, J = 7.4 Hz, 6H), 1.02 - 0.95 (m, 8H), 0.71 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 160.5, 151.8, 149.9, 138.2, 133.2, 131.2, 122.4, 114.5, 110.2, 54.8, 36.8, 33.4, 22.9, 18.2, 17.9, 13.8, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₂H₃₃NNaOSi⁺: 378.2224 (M + Na)⁺, found: 378.2230.

2-((2-butyl-5-methoxyphenyl)diisopropylsilyl)pyridine (3da)

Colorless liquid (36.2 mg, 51%). ¹H NMR (400 MHz, CDCl₃) δ 8.84 – 8.77 (m, 1H), 7.56 (td, J = 7.6, 1.7 Hz, 1H), 7.51 – 7.45 (m, 1H), 7.23 – 7.15 (m, 2H), 7.03 (d, J = 2.8 Hz, 1H), 6.89 (dd, J = 8.5, 2.8 Hz, 1H), 3.77 (s, 3H), 2.36 – 2.26 (m, 2H), 1.73 – 1.69 (m, 2H), 1.37 (ddd, J = 11.7, 10.1, 6.5 Hz, 2H), 1.08 (d, J = 7.4 Hz, 6H), 1.05 – 0.95 (m, 8H), 0.71 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.0, 156.4, 149.9, 141.8, 133.3, 133.0, 131.2, 129.5, 122.5, 122.4, 114.3, 55.1, 35.8, 33.8, 22.8, 18.2, 18.0, 13.8, 11.3. HRMS (ESI-TOF) m/z: calcd for C₂₂H₃₃NNaOSi⁺: 378.2224 (M + Na)⁺, found: 378.2216.

2-((2-butyl-4-(trifluoromethyl)phenyl)diisopropylsilyl)pyridine (3ea)

Colorless liquid (59.7 mg, 76%). ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.6 Hz, 1H), 7.59 (dt, *J* = 7.5, 3.9 Hz, 2H), 7.48 (d, *J* = 7.6 Hz, 2H), 7.41 (d, *J* = 7.9 Hz, 1H), 7.24 (ddd, *J* = 7.6, 4.9, 1.3 Hz, 1H), 2.47 – 2.40 (m, 2H), 1.75 – 1.69 (m, 2H), 1.47 – 1.36 (m, 2H), 1.07 (d, *J* = 7.4 Hz, 6H), 1.04 – 0.96 (m, 8H), 0.73 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.2, 150.6, 150.1, 137.1, 136.8, 133.5, 132.6, 131.0 (q, *J*_{CF} = 10.1 Hz), 124.9 (q, *J*_{CF} = 11.6 Hz), 122.7 (q, *J*_{CF} = 220.1 Hz), 121.1 (q, *J*_{CF} = 10.2 Hz), 99.9, 36.6, 33.3, 22.8, 18.1, 17.9, 13.7, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₂H₃₁F₃NSi⁺: 394.2172 (M + H)⁺, found: 394.2176.

2-((2-butyl-5-(trifluoromethyl)phenyl)diisopropylsilyl)pyridine (3fa)

п-Ви

Colorless liquid (47.2 mg, 60%). ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.8 Hz, 1H), 7.72 (s, 1H), 7.63 – 7.54 (m, 2H), 7.48 (d, *J* = 7.5 Hz, 1H), 7.35 (d, *J* = 8.1 Hz, 1H), 7.26 – 7.21 (m, 1H), 2.45 – 2.36 (m, 2H), 1.76 – 1.72 (m, 2H), 1.43 – 1.35 (m, 2H), 1.06 (d, *J* = 7.4 Hz, 6H), 1.01 (d, *J* = 7.3 Hz, 6H), 0.99 – 0.94 (m, 2H), 0.70 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.0, 154.0, 150.1, 133.6, 133.1 (q, *J*_{CF} = 8.4 Hz), 132.8, 131.0, 129.4, 128.8, 128.5 (q, *J*_{CF} = 9.6 Hz), 125.9 (q, *J*_{CF} = 15.1 Hz), 122.8 (q, *J*_{CF} = 274.2 Hz), 36.7, 33.3, 22.8, 18.1, 17.8, 13.7, 11.1. HRMS (ESI-TOF) m/z: calcd for C₂₂H₃₀F₃NNaSi⁺: 416.1992 (M + Na)⁺, found: 416.1986.

2-((2-butyl-4-fluorophenyl)diisopropylsilyl)pyridine (3ga)

Colorless liquid (59.7 mg, 87%). ¹H NMR (400 MHz, CDCl₃) δ 8.84 – 8.79 (m, 1H), 7.58 (td, J = 7.6, 1.7 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.22 (ddd, J = 7.6, 4.9, 1.3 Hz, 1H), 6.96 (dd, J = 11.1, 2.5 Hz, 1H), 6.88 (td, J = 8.5, 2.6 Hz, 1H), 2.42 – 2.34 (m, 2H), 1.72 – 1.67 (m, 2H), 1.45 – 1.35 (m, 2H), 1.05 (d, J = 7.4 Hz, 6H), 1.03 – 0.96 (m, 8H), 0.72 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.2, 164.8, 162.8, 152.8, 150.0, 138.5 (d, $J_{CF} =$ 7.6 Hz), 133.4 (d, $J_{CF} =$ 233.0 Hz), 131.1, 122.6, 115.3 (d, $J_{CF} =$ 19.4 Hz), 111.9 (d, $J_{CF} =$ 19.5 Hz), 36.6, 33.1, 22.8, 18.2, 17.9, 13.7, 11.3. HRMS (ESI-TOF) m/z: calcd for C₂₁H₃₀FNNaSi⁺: 366.2024 (M + Na)⁺, found: 366.2002.

2-((2-butyl-4-chlorophenyl)diisopropylsilyl)pyridine (3ha)

Colorless liquid (51.7 mg, 72%). ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.8 Hz, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.47 (d, *J* = 7.5 Hz, 1H), 7.40 (d, *J* = 8.1 Hz, 1H), 7.23 (t, *J* = 6.0 Hz, 2H), 7.16 (dd, *J* = 8.0, 1.5 Hz, 1H), 2.40 – 2.32 (m, 2H), 1.73 – 1.67 (m, 2H), 1.44 – 1.37 (m, 2H), 1.05 (d, *J* = 7.4 Hz, 6H), 1.03 – 0.96 (m, 8H), 0.72 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 151.9, 150.0, 138.0, 135.6, 133.5, 131.1, 130.0, 128.7, 124.9, 122.6, 36.5, 33.2, 22.8, 18.1, 17.9, 13.7, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₁H₃₀ClNNaSi⁺: 382.1728 (M + Na)⁺, found: 382.1721.

2-((2-butyl-5-chlorophenyl)diisopropylsilyl)pyridine (3ia)

Colorless liquid (57.5 mg, 80%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (dd, J = 3.3, 1.1 Hz, 1H), 7.58 (td, J = 7.6, 1.7 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.41 (d, J = 2.3 Hz, 1H), 7.28 (dd, J = 8.3, 2.3 Hz, 1H), 7.22 (ddd, J = 7.6, 4.9, 1.3 Hz, 1H), 7.18 (d, J = 8.3 Hz, 1H), 2.37 – 2.29 (m, 2H), 1.74 – 1.68 (m, 2H), 1.40 – 1.31 (m, 2H), 1.07 (d, J = 7.4 Hz, 6H), 1.04 – 0.96 (m, 8H), 0.70 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.3, 150.1, 148.1, 136.0, 134.5, 133.5, 131.0, 130.9, 130.1, 129.2, 122.7, 36.1, 33.5, 22.8, 18.2, 17.9, 13.7, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₁H₃₀CINNaSi⁺: 383.1728 (M + Na)⁺, found: 382.1718.

2-((4-bromo-2-butylphenyl)diisopropylsilyl)pyridine (3ja)

Colorless liquid (41.1 mg, 51%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, J = 4.6 Hz, 1H), 7.57 (td, J = 7.6, 1.3 Hz, 1H), 7.46 (d, J = 7.5 Hz, 1H), 7.39 (d, J = 1.2 Hz, 1H), 7.35 – 7.28 (m, 2H), 7.22 (dd, J = 6.4, 5.2 Hz, 1H), 2.40 – 2.31 (m, 2H), 1.73 – 1.65 (m, 2H), 1.44 – 1.34 (m, 2H), 1.05 (d, J = 7.4 Hz, 6H), 1.02 – 0.98 (m, 8H), 0.72 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 152.1, 150.1, 138.2, 133.4, 131.6, 131.1, 130.6, 127.8, 124.3, 122.6, 36.5, 33.3, 22.8, 18.1, 17.9, 13.7, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₁H₃₀BrNNaSi⁺: 426.1223 (M + Na)⁺, found: 426.1224.

2-((3-butyl-[1,1'-biphenyl]-4-yl)diisopropylsilyl)pyridine (3ka)

Colorless liquid (65.8 mg, 82%). ¹H NMR (400 MHz, CDCl₃) δ 8.83 (d, *J* = 4.7 Hz, 1H), 7.65 – 7.58 (m, 3H), 7.55 (dt, *J* = 10.5, 4.6 Hz, 2H), 7.48 (d, *J* = 1.5 Hz, 1H), 7.46 – 7.39 (m, 3H), 7.34 (t, *J* = 7.3 Hz, 1H), 7.25 – 7.20 (m, 1H), 2.50 – 2.40 (m, 2H), 1.82 - 1.74 (m, 2H), 1.48 (ddd, *J* = 11.9, 10.1, 6.6 Hz, 2H), 1.10 (d, *J* = 7.4 Hz, 6H), 1.08 – 1.01 (m, 8H), 0.74 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 150.3, 150.0, 141.8, 141.2, 137.3, 133.3, 131.2, 130.3, 128.6, 127.4, 127.2, 127.1, 123.4, 122.5, 36.9, 33.7, 23.0, 18.9, 18.0, 13.8, 11.3. HRMS (ESI-TOF) m/z: calcd for C₂₇H₃₅NNaSi⁺: 424.2431 (M + Na)⁺, found: 424.2430.

ethyl 3-butyl-4-(diisopropyl(pyridin-2-yl)silyl)benzoate (3la)

Colorless liquid (77.1 mg, 87%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, *J* = 4.8 Hz, 1H), 7.90 (d, *J* = 1.3 Hz, 1H), 7.81 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.58 (td, *J* = 7.8, 1.9 Hz, 2H), 7.46 (d, *J* = 7.6 Hz, 1H), 7.22 (ddd, *J* = 7.6, 4.9, 1.3 Hz, 1H), 4.37 (q, *J* = 7.1 Hz, 2H), 2.47 – 2.39 (m, 2H), 1.76 – 1.72 (m, 2H), 1.50 – 1.36 (m, 5H), 1.06 (d, *J* = 7.4 Hz, 6H), 1.03 – 0.95 (m, 8H), 0.72 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.0, 164.4, 150.2, 150.1, 138.1, 136.8, 133.4, 131.1, 131.0, 129.2, 125.2, 122.6, 60.8, 36.6, 33.5, 22.9, 18.1, 17.9, 14.3, 13.7, 11.3. HRMS (ESI-TOF) m/z: calcd for C₂₄H₃₅NNaO₂Si⁺: 420.2329 (M + Na)⁺, found: 420.2333.

3-butyl-4-(diisopropyl(pyridin-2-yl)silyl)-*N*,*N*-diisopropylbenzamide (3ma)

Colorless liquid (67.8 mg, 75%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, J = 4.5 Hz, 1H), 7.59 (td, J = 7.6, 1.7 Hz, 1H), 7.51 (d, J = 7.5 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.22 (ddd, J = 7.5, 4.9, 1.3 Hz, 1H), 7.18 (d, J = 1.2 Hz, 1H), 7.10 (dd, J = 7.6, 1.5 Hz, 1H), 3.96 (s, 1H), 3.50 (s, 1H), 2.42 – 2.34 (m, 2H), 1.69 (d, J = 7.4 Hz, 2H), 1.49 (s, 6H), 1.44 – 1.38 (m, 2H), 1.15 (s, 6H), 1.06 (d, J = 7.4 Hz, 6H), 1.03 – 0.94 (m, 8H), 0.71 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 171.3, 164.7, 150.2, 150.0, 139.4, 136.9, 133.5, 132.3, 131.1, 125.8, 122.6, 121.8, 36.7, 33.4, 29.6, 22.9, 20.7, 18.1, 17.8, 13.7, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₈H₄₄N₂NaOSi⁺: 475.3115 (M + Na)⁺, found: 475.3113.

2-((2-butyl-4,5-dimethylphenyl)diisopropylsilyl)pyridine (3na)

Colorless liquid (54.4 mg, 77%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, J = 4.5 Hz, 1H), 7.54 (d, J = 1.7 Hz, 1H), 7.47 (s, 1H), 7.22 (s, 1H), 7.19 (ddd, J = 7.4, 4.9, 1.3 Hz, 1H), 7.03 (s, 1H), 2.34 – 2.27

(m, 2H), 2.25 (s, 3H), 2.23 (s, 3H), 1.74 – 1.69 (m, 2H), 1.42 – 1.35 (m, 2H), 1.06 (d, J = 7.4 Hz, 6H), 1.03 – 0.94 (m, 8H), 0.71 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 149.8, 147.3, 138.0, 137.6, 133.1, 132.5, 131.2, 130.1, 128.2, 122.3, 36.3, 33.8, 22.9, 19.7, 19.4, 18.3, 18.0, 13.8, 11.3. HRMS (ESI-TOF) m/z: calcd for C₂₃H₃₅NNaSi⁺: 376.2431 (M + Na)⁺, found: 376.2422.

2-((2-butyl-4-fluoro-5-methylphenyl)diisopropylsilyl)pyridine (30a)

Colorless liquid (37.2 mg, 52%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, *J* = 4.6 Hz, 1H), 7.57 (td, *J* = 7.6, 1.7 Hz, 1H), 7.47 (d, *J* = 7.5 Hz, 1H), 7.21 (ddd, *J* = 7.5, 6.6, 3.5 Hz, 2H), 6.90 (d, *J* = 11.8 Hz, 1H), 2.37 – 2.28 (m, 2H), 2.23 (s, 3H), 1.73 – 1.69 (m, 2H), 1.42 – 1.32 (m, 2H), 1.05 (d, *J* = 7.4 Hz, 6H), 0.99 (d, *J* = 7.4 Hz, 6H), 0.94 (dd, *J* = 12.7, 5.5 Hz, 2H), 0.71 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.9, 163.7, 161.3, 150.0, 139.9 (d, *J*_{CF} = 5.4 Hz), 133.3 (d, *J*_{CF} = 232.0 Hz), 131.0, 126.5 (d, *J*_{CF} = 4.4 Hz) 122.5, 120.8 (d, *J*_{CF} = 15.9 Hz), 115.0 (d, *J*_{CF} = 20.3 Hz), 36.2, 33.2, 22.8, 18.2, 17.9, 14.3 (d, *J*_{CF} = 3.2 Hz), 13.7, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₂H₃₃FNSi⁺: 358.2361 (M + H)⁺, found: 358.2356.

2-((3-butylnaphthalen-2-yl)diisopropylsilyl)pyridine (3pa)

Colorless liquid (37.5 mg, 49%). ¹H NMR (400 MHz, CDCl₃) δ 8.83 (dd, J = 3.5, 1.3 Hz, 1H), 8.04 (s, 1H), 7.82 – 7.72 (m, 2H), 7.69 (d, J = 10.2 Hz, 1H), 7.61 – 7.53 (m, 1H), 7.52 – 7.37 (m, 3H), 7.23 (ddd, J = 7.5, 4.9, 1.4 Hz, 1H), 2.59 – 2.51 (m, 2H), 1.86 – 1.81 (m, 2H), 1.52 (ddd, J = 12.3, 10.3, 6.6 Hz, 2H), 1.15 – 1.10 (m, 6H), 1.10 – 1.01 (m, 8H), 0.76 (t, J = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 150.0, 145.7, 137.9, 134.0, 133.3, 131.6, 131.2, 131.0, 127.9, 126.9, 126.4, 126.0, 124.8, 122.5, 36.4, 33.3, 22.8, 18.4, 18.2, 13.8, 11.5. HRMS (ESI-TOF) m/z: calcd for C₂₅H₃₃NNaSi⁺: 398.2274 (M + Na)⁺, found: 398.2283.

2-((2-hexylphenyl)diisopropylsilyl)pyridine (3ab)

Colorless liquid (57.9 mg, 82%). ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, J = 4.5 Hz, 1H), 7.56 (td, J = 7.6, 1.7 Hz, 1H), 7.51 – 7.45 (m, 2H), 7.36 – 7.30 (m, 1H), 7.26 – 7.14 (m, 3H), 2.42 – 2.34 (m, 2H), 1.76 – 1.69 (m, 2H), 1.47 – 1.37 (m, 2H), 1.19 (dd, J = 14.6, 7.3 Hz, 2H), 1.12 – 1.05 (m, 8H), 1.04 – 0.95 (m, 8H), 0.82 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.2, 149.9, 149.9, 136.8, 133.3, 131.5, 131.1, 129.2, 128.6, 124.6, 122.4, 37.1, 31.6, 31.5, 29.5, 22.5, 18.2, 18.0, 14.0, 11.3. HRMS (ESI-TOF) m/z: calcd for C₂₃H₃₅NNaSi⁺: 376.2431 (M + Na)⁺, found: 376.2419.

2-(diisopropyl(2-phenethylphenyl)silyl)pyridine (3ac)

Colorless liquid (43.3 mg, 58%). ¹H NMR (400 MHz, CDCl₃) δ 8.82 (d, *J* = 4.6 Hz, 1H), 7.59 – 7.50 (m, 3H), 7.38 (d, *J* = 6.6 Hz, 2H), 7.21 – 7.09 (m, 5H), 6.82 (d, *J* = 7.0 Hz, 2H), 2.76 (s, 4H), 1.74 – 1.70 (m, 2H), 1.09 (d, *J* = 7.4 Hz, 6H), 1.01 (d, *J* = 7.3 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 165.0, 150.1, 148.6, 141.9, 136.9, 133.5, 131.7, 131.1, 129.4, 128.9, 128.1, 128.0, 125.6, 125.0, 122.6, 38.4, 37.5, 18.3, 18.0, 11.3. HRMS (ESI-TOF) m/z: calcd for C₂₅H₃₁NNaSi⁺: 396.2118 (M + Na)⁺, found: 396.2115.

2-(diisopropyl(2-(4-phenylbutyl)phenyl)silyl)pyridine (3ad)

Colorless liquid (52.1 mg, 65%). ¹H NMR (400 MHz, CDCl₃) δ 8.79 (d, J = 4.8 Hz, 1H), 7.48 (dd, J = 14.2, 7.4 Hz, 3H), 7.37 – 7.30 (m, 1H), 7.28 – 7.23 (m, 2H), 7.23 – 7.12 (m, 4H), 7.08 (d, J = 7.1 Hz, 2H), 2.41 (dd, J = 14.9, 7.2 Hz, 4H), 1.75 – 1.70 (m, 2H), 1.47 (dd, J = 8.1, 3.6 Hz, 2H), 1.27 (d, J = 6.6 Hz, 2H), 1.06 (d, J = 7.4 Hz, 6H), 1.01 (t, J = 6.2 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 149.9, 149.5, 142.5, 136.7, 133.3, 131.4, 131.1, 129.3, 128.6, 128.3, 128.1, 125.5, 124.7, 122.5, 37.0, 35.7, 31.7, 31.1, 18.2, 17.9, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₇H₃₅NNaSi⁺: 424.2431 (M + Na)⁺, found: 424.2437.

2-(diisopropyl(2-(4-methoxybutyl)phenyl)silyl)pyridine (3ae)

Colorless liquid (49.7 mg, 70%). ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.4 Hz, 1H), 7.56 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.51 – 7.46 (m, 2H), 7.36 – 7.30 (m, 1H), 7.26 (t, *J* = 3.5 Hz, 1H), 7.23 – 7.14 (m, 2H), 3.26 (s, 3H), 3.17 (t, *J* = 6.7 Hz, 2H), 2.44 – 2.37 (m, 2H), 1.75 – 1.69 (m, 2H), 1.54 – 1.44 (m, 2H), 1.26 (dd, *J* = 9.3, 5.5 Hz, 2H), 1.08 – 1.05 (m, 6H), 1.00 (d, *J* = 7.4 Hz, 6H). ¹³C NMR (100

MHz, CDCl₃) δ 171.3, 164.7, 150.0, 139.4, 136.9, 133.5, 132.3, 131.1, 125.8, 122.6, 121.8, 36.7, 33.4, 22.9, 20.7, 18.1, 17.8, 13.7, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₂H₃₃NNaOSi⁺: 378.2224 (M + Na)⁺, found: 378.2225.

5-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)pentanenitrile (3af)

Colorless liquid (49.7 mg, 71%). ¹H NMR (400 MHz, CDCl₃) δ 8.82 (d, J = 4.7 Hz, 1H), 7.61 (td, J = 7.6, 1.7 Hz, 1H), 7.51 (dd, J = 11.3, 7.6 Hz, 2H), 7.38 – 7.31 (m, 1H), 7.26 – 7.19 (m, 3H), 2.42 – 2.35 (m, 2H), 2.10 (t, J = 7.2 Hz, 2H), 1.74 – 1.69 (m, 2H), 1.53 (ddd, J = 11.7, 10.1, 6.5 Hz, 2H), 1.26 (dd, J = 15.2, 7.4 Hz, 2H), 1.06 (d, J = 7.4 Hz, 6H), 1.01 (d, J = 7.4 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 165.2, 150.0, 148.1, 136.8, 133.6, 131.6, 131.0, 129.4, 128.5, 125.1, 122.6, 119.4, 36.0, 30.4, 25.4, 18.2, 17.9, 16.8, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₂H₃₀N₂NaSi⁺: 373.2070 (M + Na)⁺, found: 373.2045.

2-((2-(4-(furan-2-yl)butyl)phenyl)diisopropylsilyl)pyridine (3ag)

Colorless liquid (17.2 mg, 22%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, *J* = 4.7 Hz, 1H), 7.54 (td, *J* = 7.6, 1.6 Hz, 1H), 7.48 (t, *J* = 7.9 Hz, 2H), 7.33 (t, *J* = 7.5 Hz, 1H), 7.28 (d, *J* = 1.0 Hz, 1H), 7.25 – 7.16 (m, 3H), 6.29 – 6.23 (m, 1H), 5.89 (d, *J* = 2.6 Hz, 1H), 2.45 – 2.38 (m, 4H), 1.72 – 1.68(m, 2H), 1.47 (ddd, *J* = 11.5, 10.2, 6.4 Hz, 2H), 1.32 – 1.26 (m, 2H), 1.06 (d, *J* = 7.4 Hz, 6H), 1.00 (d, *J* = 7.3 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 156.2, 150.0, 149.4, 140.5, 136.8, 133.3, 131.5, 131.1, 129.3, 128.6, 124.7, 122.5, 110.0, 104.5, 36.8, 31.0, 28.2, 27.7, 18.2, 18.0, 11.3. HRMS (ESI-TOF) m/z: calcd for C₂₅H₃₃NNaOSi⁺: 414.2224 (M + Na)⁺, found: 414.2226.

2-(4-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)butyl)isoindoline-1,3-dione (3ah)

Colorless liquid (43.2 mg, 46%). ¹H NMR (400 MHz, CDCl₃) δ 8.78 (d, *J* = 4.5 Hz, 1H), 7.83 (dd, *J* = 5.3, 3.1 Hz, 2H), 7.71 (dd, *J* = 5.3, 3.1 Hz, 2H), 7.55 (t, *J* = 7.3 Hz, 1H), 7.48 (t, *J* = 8.2 Hz, 2H), 7.32 (t, *J* = 7.4 Hz, 1H), 7.24 – 7.14 (m, 3H), 3.49 (t, *J* = 7.2 Hz, 2H), 2.43 – 2.34 (m, 2H), 1.74 – 1.66 (m, 2H), 1.43 (dt, *J* = 15.9, 9.0 Hz, 2H), 1.29 (d, *J* = 7.2 Hz, 2H), 1.04 (d, *J* = 7.4 Hz, 6H), 0.98 (d, *J* = 7.3 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 168.2, 150.0, 149.0, 136.7, 133.8, 133.4, 132.1,

131.5, 131.0, 129.7, 129.3, 128.7, 124.9, 123.1, 122.7, 37.7, 36.6, 29.6, 28.8, 18.2, 17.9, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₉H₃₄N₂NaO₂Si⁺: 493.2282 (M + Na)⁺, found: 493.2282.

1-(4-(4-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)butoxy)phenyl)ethanone (3ai)

Colorless liquid (47.7 mg, 52%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, *J* = 4.6 Hz, 1H), 7.92 (d, *J* = 8.8 Hz, 2H), 7.53 (dt, *J* = 16.6, 7.2 Hz, 3H), 7.35 (t, *J* = 7.4 Hz, 1H), 7.27 (d, *J* = 4.7 Hz, 1H), 7.19 (dd, *J* = 12.3, 5.1 Hz, 2H), 6.85 (d, *J* = 8.8 Hz, 2H), 3.82 (t, *J* = 6.4 Hz, 2H), 2.56 (s, 3H), 2.49 – 2.42 (m, 2H), 1.75 – 1.69 (m, 4H), 1.53 – 1.45 (m, 2H), 1.06 (d, *J* = 7.4 Hz, 6H), 1.00 (d, *J* = 7.3 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 196.8, 165.1, 162.9, 162.4, 150.0, 149.0, 136.8, 133.4, 131.5, 131.1, 130.5, 129.3, 128.5, 124.9, 122.5, 114.0, 67.7, 36.6, 29.1, 27.8, 26.3, 18.2, 17.9, 11.2. HRMS (ESI-TOF) m/z: calcd for C₂₉H₃₇NNaO₂Si⁺: 482.2486 (M + Na)⁺, found: 482.2493.

7-(4-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)butoxy)-4-methyl-2H-chromen-2-one (3aj)

Colorless liquid (68.8 mg, 69%). ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.6 Hz, 1H), 7.57 (t, *J* = 7.0 Hz, 1H), 7.49 (dd, *J* = 14.9, 8.4 Hz, 3H), 7.35 (t, *J* = 7.4 Hz, 1H), 7.28 (s, 1H), 7.20 (t, *J* = 7.5 Hz, 2H), 6.79 (dd, *J* = 8.8, 2.3 Hz, 1H), 6.72 (d, *J* = 2.2 Hz, 1H), 6.13 (s, 1H), 3.80 (t, *J* = 6.3 Hz, 2H), 2.51 – 2.42 (m, 2H), 2.40 (s, 3H), 1.75 – 1.71 (m, 2H), 1.62 (dd, *J* = 10.2, 5.8 Hz, 2H), 1.51 (dd, *J* = 13.8, 6.6 Hz, 2H), 1.06 (d, *J* = 7.4 Hz, 6H), 1.01 (d, *J* = 7.3 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 162.0, 161.3, 155.2, 152.5, 150.0, 148.9, 136.8, 133.4, 131.5, 131.1, 129.4, 128.5, 125.4, 124.9, 122.6, 113.3, 112.6, 111.8, 101.2, 68.1, 36.6, 29.0, 27.7, 18.6, 18.2, 17.9, 11.2. HRMS (ESI-TOF) m/z: calcd for C₃₁H₃₇NNaO₃Si⁺: 522.2435 (M + Na)⁺, found: 522.2430.

(8S,9S,13S,14S)-3-(4-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)butoxy)-7,8,9,11,12,13,15,16-octa hydro-6H-cyclopenta[a]phenanthren-17(14H)-one (3ak)

Colorless liquid (82.2 mg, 71%). ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, *J* = 4.6 Hz, 1H), 7.55 (t, *J* = 7.5 Hz, 1H), 7.49 (t, *J* = 6.8 Hz, 2H), 7.34 (t, *J* = 7.2 Hz, 1H), 7.27 (s, 1H), 7.19 (t, *J* = 7.1 Hz, 3H),

6.64 (d, J = 8.4 Hz, 1H), 6.58 (s, 1H), 3.74 (t, J = 6.5 Hz, 2H), 2.88 (d, J = 9.4 Hz, 2H), 2.55 – 2.48 (m, 1H), 2.48 – 2.42 (m, 2H), 2.39 (d, J = 9.6 Hz, 1H), 2.23 (d, J = 11.8 Hz, 1H), 2.06 (dddd, J = 23.4, 20.4, 12.2, 3.6 Hz, 6H), 1.74 – 1.70 (m, 3H), 1.47 – 1.42 (m, 3H), 1.06 (d, J = 7.4 Hz, 6H), 1.00 (t, J = 7.0 Hz, 6H), 0.97 (d, J = 7.5 Hz, 1H), 0.91 (s, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 165.1, 156.9, 156.7, 150.0, 149.2, 137.6, 136.8, 133.4, 131.8, 131.4, 131.1, 129.3, 128.6, 126.2, 124.8, 122.5, 114.4, 112.0, 67.4, 50.3, 48.0, 43.9, 38.3, 36.7, 35.8, 31.5, 29.6, 29.4, 27.8, 26.5, 25.9, 21.5, 18.2, 17.9, 13.8, 11.2. HRMS (ESI-TOF) m/z: calcd for C₃₈H₅₀NO₂Si⁺: 580.3605 (M + H)⁺, found: 580.3630.

2-((2-butylphenyl)diethylsilyl)pyridine (5aa)

Colorless liquid (17.8 mg, 30%). ¹H NMR (400 MHz, CDCl₃) δ 8.78 (d, *J* = 4.8 Hz, 1H), 7.56 – 7.49 (m, 2H), 7.41 (d, *J* = 7.5 Hz, 1H), 7.36 – 7.30 (m, 1H), 7.23 – 7.15 (m, 3H), 2.50 – 2.42 (m, 2H), 1.26 – 1.15 (m, 6H), 1.08 (dd, *J* = 14.9, 7.4 Hz, 2H), 0.97 (t, *J* = 7.8 Hz, 6H), 0.72 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 166.5, 150.1, 149.4, 135.9, 133.7, 133.2, 130.3, 129.5, 128.5, 124.9, 122.5, 36.2, 34.1, 22.8, 13.8, 7.4, 4.0. HRMS (ESI-TOF) m/z: calcd for C₁₉H₂₇NNaSi⁺: 320.1805 (M + Na)⁺, found: 320.1778.

2-((2-butylphenyl)(isobutyl)(methyl)silyl)pyridine (5ba)

Colorless liquid (24.9 mg, 40%). ¹H NMR (400 MHz, CDCl₃) δ 8.78 (d, *J* = 4.8 Hz, 1H), 7.56 – 7.49 (m, 2H), 7.40 (d, *J* = 7.5 Hz, 1H), 7.35 – 7.30 (m, 1H), 7.21 – 7.15 (m, 3H), 2.54 – 2.46 (m, 2H), 1.80 (dt, *J* = 13.3, 6.6 Hz, 1H), 1.25 (dd, *J* = 6.8, 2.7 Hz, 4H), 1.16 – 1.08 (m, 2H), 0.88 (t, *J* = 6.1 Hz, 6H), 0.74 (t, *J* = 7.2 Hz, 3H), 0.66 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 150.0, 149.1, 135.5, 134.8, 133.8, 129.9, 129.5, 128.5, 125.0, 122.5, 36.2, 34.0, 26.3, 26.2, 24.8, 24.2, 22.8, 13.9. HRMS (ESI-TOF) m/z: calcd for C₂₀H₂₉NNaSi⁺: 334.1961 (M + Na)⁺, found: 334.1956.

2-(butyl(methyl)(pentyl)silyl)pyridine (7aa)

Colorless liquid (17.9 mg, 36%). ¹H NMR (400 MHz, CDCl₃) δ 8.78 (d, *J* = 4.7 Hz, 1H), 7.58 (t, *J* = 7.5 Hz, 1H), 7.47 (d, *J* = 7.5 Hz, 1H), 7.21 – 7.15 (m, 1H), 1.29 (dd, *J* = 11.8, 4.2 Hz, 14H), 0.85 (d, *J* = 6.1 Hz, 6H), 0.30 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 150.1, 133.7, 130.8, 129.3, 122.5, 35.8,

26.5, 26.0, 23.4, 22.2, 13.9, 13.7, 13.3, 13.2, -5.6. HRMS (ESI-TOF) m/z: calcd for $C_{15}H_{28}NSi^+$: 250.1986 (M + H)⁺, found: 250.1981.

2-((2-butylphenyl)dimethylgermyl)pyridine (9aa)

Colorless liquid (16.4 mg, 26%). ¹H NMR (400 MHz, CDCl₃) δ 8.76 (d, *J* = 4.8 Hz, 1H), 7.53 (td, *J* = 7.6, 1.7 Hz, 1H), 7.45 (t, *J* = 6.6 Hz, 1H), 7.38 (d, *J* = 7.5 Hz, 1H), 7.30 (dd, *J* = 11.2, 3.8 Hz, 1H), 7.18 (ddd, *J* = 7.8, 7.2, 5.3 Hz, 3H), 2.59 – 2.50 (m, 2H), 1.37 – 1.32 (m, 2H), 1.22 – 1.16 (m, 2H), 0.78 (t, *J* = 7.3 Hz, 3H), 0.74 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 150.2, 148.3, 137.6, 134.4, 134.2, 132.0, 129.2, 129.0, 128.6, 125.2, 122.5, 36.5, 34.3, 29.6, 22.7, 13.9, -1.9. HRMS (ESI-TOF) m/z: calcd for C₁₇H₂₄GeN⁺: 316.1115 (M + H)⁺, found: 316.1122.

VI. Removal of directing group

An oven dried 10 ml Wheaton V-vial was charged with **3ia** or **3ac** (0.20 mmol), AgF (104 mg, 0.80 mmol), and regular MeOH (1.0 ml) under argon atmosphere. The mixture was stirred overnight in the dark at room temperature. After completion, the mixture was filtered through celite and concentrated. The residue was purified by silica gel chromatography to afford the product.

1-butyl-4-chlorobenzene (10ia)

Colorless liquid (32 mg, 96%)¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, *J* = 8.2 Hz, 2H), 7.16 (d, *J* = 8.2 Hz, 2H), 2.64 (t, *J* = 7.7 Hz, 2H), 1.70 – 1.59 (m, 2H), 1.48 – 1.36 (m, 2H), 1.01 (td, *J* = 7.2, 0.9 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 141.2, 131.2, 129.6, 128.2, 34.9, 33.5, 22.2, 13.8.

1,2-diphenylethane (10ac)

White solid (33 mg, 91%)¹H NMR (400 MHz, CDCl₃) δ 7.40 (dd, J = 6.5, 2.8 Hz, 4H), 7.36 – 7.27 (m, 6H), 3.05 (d, J = 3.0 Hz, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 141.7, 128.4, 128.2, 125.8, 37.9.

VII. NMR Spectra

2-(diisopropyl(phenyl)silyl)pyridine (1a)

¹H NMR (CDCl₃)

2-(diisopropyl(*p*-tolyl)silyl)pyridine (1b)

2-(diisopropyl(4-methoxyphenyl)silyl)pyridine (1c)

2-(diisopropyl(3-methoxyphenyl)silyl)pyridine (1d)

2-(diisopropyl(4-(trifluoromethyl)phenyl)silyl)pyridine (1e)

2-(diisopropyl(3-(trifluoromethyl)phenyl)silyl)pyridine (1f)

¹H NMR (CDCl₃)

2-((4-fluorophenyl)diisopropylsilyl)pyridine (1g)

2-((4-chlorophenyl)diisopropylsilyl)pyridine (1h)

2-((3-chlorophenyl)diisopropylsilyl)pyridine (1i)

2-((4-bromophenyl)diisopropylsilyl)pyridine (1j)









2-([1,1'-biphenyl]-4-yldiisopropylsilyl)pyridine (1k)









ethyl 4-(diisopropyl(pyridin-2-yl)silyl)benzoate (11)





4-(diisopropyl(pyridin-2-yl)silyl)-N,N-diisopropylbenzamide (1m)







2-((3,4-dimethylphenyl)diisopropylsilyl)pyridine (1n)





(2, 2)(2, 2)(2, 2)(2, 2)(2, 2)(3, 2)(





2-((4-fluoro-3-methylphenyl)diisopropylsilyl)pyridine (10)

¹H NMR (CDCl₃)





2-(diisopropyl(naphthalen-2-yl)silyl)pyridine (1p)









2-(diethyl(phenyl)silyl)pyridine (4a)

¹H NMR (CDCl₃)





2-(isobutyl(methyl)(phenyl)silyl)pyridine (4b)





2-(butyldimethylsilyl)pyridine (6a)



150 140



60 50

-10

2-(dimethyl(phenyl)germyl)pyridine (8a)



 $10.0 \ 9.5 \ 9.0 \ 8.5 \ 8.0 \ 7.5 \ 7.0 \ 5.5 \ 5.0 \ 5.5 \ 5.0 \ 4.5 \ 4.0 \ 3.5 \ 3.0 \ 2.5 \ 2.0 \ 1.5 \ 1.0 \ 0.5 \ 5.0 \ 5.5 \ 5.5$





(4-phenylbutyl)boronic acid (2d)



¹³C NMR (d_6 -DMSO)



(4-methoxybutyl)boronic acid (2e)



¹³C NMR (d_6 -DMSO)



(4-cyanobutyl)boronic acid (2f)



¹³C NMR (d_6 -DMSO)



(4-(furan-2-yl)butyl)boronic acid (2g)

¹H NMR (d_6 -DMSO)





4-(1,3-dioxoisoindolin-2-yl)butylboronic acid (2h)



¹³C NMR (d_6 -DMSO)



(4-(4-acetylphenoxy)butyl)boronic acid (2i)





(4-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)butyl)boronic acid (2j)



(4-(((8S,9R,13R,14R)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a] phenanthren-3-yl)oxy)butyl)boronic acid (2k) ¹H NMR (*d*₆-DMSO)



¹³C NMR (d_6 -DMSO)



2-((2-butylphenyl)diisopropylsilyl)pyridine (3aa)





2-((2-butyl-4-methylphenyl)diisopropylsilyl)pyridine (3ba)









2-((2-butyl-4-methoxyphenyl)diisopropylsilyl)pyridine (3ca)





2-((2-butyl-5-methoxyphenyl)diisopropylsilyl)pyridine (3da)





2-((2-butyl-4-(trifluoromethyl)phenyl)diisopropylsilyl)pyridine (3ea)



200 190

170 160

130 120



70 60

40 30

2-((2-butyl-5-(trifluoromethyl)phenyl)diisopropylsilyl)pyridine (3fa)







2-((2-butyl-4-fluorophenyl)diisopropylsilyl)pyridine (3ga)

¹H NMR (CDCl₃)





2-((2-butyl-4-chlorophenyl)diisopropylsilyl)pyridine (3ha)



140 130

2-((2-butyl-5-chlorophenyl)diisopropylsilyl)pyridine (3ia)

¹H NMR (CDCl₃)





2-((4-bromo-2-butylphenyl)diisopropylsilyl)pyridine (3ja)

¹H NMR (CDCl₃)





2-((3-butyl-[1,1'-biphenyl]-4-yl)diisopropylsilyl)pyridine (3ka)

¹H NMR (CDCl₃)





ethyl 3-butyl-4-(diisopropyl(pyridin-2-yl)silyl)benzoate (3la)





3-butyl-4-(diisopropyl(pyridin-2-yl)silyl)-*N*,*N*-diisopropylbenzamide (3ma)







2-((2-butyl-4,5-dimethylphenyl)diisopropylsilyl)pyridine (3na)

¹H NMR (CDCl₃)





2-((2-butyl-4-fluoro-5-methylphenyl)diisopropylsilyl)pyridine (3oa)

¹H NMR (CDCl₃)





2-((3-butylnaphthalen-2-yl)diisopropylsilyl)pyridine (3pa)



200 190

140 130



40 30

2-((2-hexylphenyl)diisopropylsilyl)pyridine (3ab)






2-(diisopropyl(2-phenethylphenyl)silyl)pyridine (3ac)





2-(diisopropyl(2-(4-phenylbutyl)phenyl)silyl)pyridine (3ad)





2-(diisopropyl(2-(4-methoxybutyl)phenyl)silyl)pyridine (3ae)

¹H NMR (CDCl₃)





5-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)pentanenitrile (3af)

¹H NMR (CDCl₃)





2-((2-(4-(furan-2-yl)butyl)phenyl)diisopropylsilyl)pyridine (3ag)

¹H NMR (CDCl₃)





2-(4-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)butyl)isoindoline-1,3-dione (3ah)



1-(4-(4-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)butoxy)phenyl)ethanone (3ai) ¹H NMR (CDCl₃)







7-(4-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)butoxy)-4-methyl-2H-chromen-2-one (3aj)





(8S,9S,13S,14S)-3-(4-(2-(diisopropyl(pyridin-2-yl)silyl)phenyl)butoxy)-7,8,9,11,12,13,15,16-octa hydro-6H-cyclopenta[a]phenanthren-17(14H)-one (3ak) ¹H NMR (CDCl₃)



2-((2-butylphenyl)diethylsilyl)pyridine (5aa)







2-((2-butylphenyl)(isobutyl)(methyl)silyl)pyridine (5ba)







2-(butyl(methyl)(pentyl)silyl)pyridine (7aa)





2-((2-butylphenyl)dimethylgermyl)pyridine (9aa)





1-butyl-4-chlorobenzene (10ia)



¹³C NMR (CDCl₃)



1,2-diphenylethane (10ac)

¹H NMR (CDCl₃)



